Hereditary Cancer Testing
Our sister company, GeneDx, a subsidiary of BioReference Laboratories, Inc. and an OPKO Health company, has developed comprehensive panels to test key genes associated with increased susceptibility to many cancer sub-types.
With high quality testing, expertise, and experience, GeneDx has performed over 184,000 hereditary cancer tests to date
GeneDx Is A Pioneer In The Inherited Disorders Industry
- GeneDx was the first to commercially launch next-generation sequencing (NGS) in 2008
- GeneDx co-founders are thought-leaders and are co-authors of established guidelines, such as the ACMG guidelines on NGS
GeneDx Development Timeline
GenPath Hereditary Cancer Panels Provide Accurate Results With Industry-Leading Turn-Around Times
View test options for hereditary cancer panels
*Testing includes sequencing and deletion duplication for all genes except EPCAM (del/dup only),
MITF (evaluation of c.952G>A only), and SCG5/GREM1 (del/dup only).
See a complete list of hereditary cancer panels offered by GeneDx: